Mark W. Womack, CEO of BioCina, highlights the strategic advantages of operating in Australia, including strong government support and tax incentives; robust biomanufacturing capacity; and a collaborative, innovation-focused life sciences ecosystem.
Mark W. Womack, CEO of BioCina, highlights the strategic advantages of operating in Australia, including strong government support and tax incentives; robust biomanufacturing capacity; and a collaborative, innovation-focused life sciences ecosystem.
